Tine Lindgreen

About

#### Commit Biologics In biology the complement system (a series of internal processes that help fight infection) represents an efficient immune mechanism for clearing tumour cells, modulating the tumor-microenvironment and for stimulating an adaptive immune response. Activating the complement system has been a big obstacle in cancer therapy. Commit Biologics has developed a novel platform technology to potently activate the complement system on a target of choice. This tech has the potential to create a new type of immunotherapy for a wide variety of cancers. ### Tine Marie Kjærgaard Lindgreen, principal at Seed Capital Seed Capital is Denmark's largest seed-focused venture capital firm, investing only in Denmark-based companies. [...] A landscape headshot of a smiling Tine Marie Kjærgaard Lindgreen, principal at SEED Capital #### ZTLment Blockchain has the potential to be the building block within several industries. The technological progress within blockchain doesn’t show any sign of slowing down, and within fintech its adoption is on the rise. In Denmark, however, blockchain adoption is still relatively immature, and a few Danish companies are paving the way. [...] #### Synklino Synklino is developing a new treatment that can eradicate cytomegalovirus (CMV), a significant unmet need for transplant patients. Synklino targets a receptor called US28, which is expressed by cells infected with CMV virus. For transplant recipients, CMV causes suboptimal transplantation